PTC Therapeutics, Inc. Share Price

Equities

PTCT

US69366J2006

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 21/06/2024 BST 5-day change 1st Jan Change
36.52 USD +9.70% Intraday chart for PTC Therapeutics, Inc. +1.98% +32.51%
Sales 2024 * 752M 59.48B Sales 2025 * 843M 66.67B Capitalization 2.8B 222B
Net income 2024 * -382M -30.21B Net income 2025 * -203M -16.05B EV / Sales 2024 * 3.04 x
Net cash position 2024 * 512M 40.53B Net cash position 2025 * 395M 31.22B EV / Sales 2025 * 2.85 x
P/E ratio 2024 *
-7.26 x
P/E ratio 2025 *
-12.9 x
Employees 1,022
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.58%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on PTC Therapeutics, Inc.

1 day+9.70%
1 week+1.98%
Current month+0.44%
1 month-5.49%
3 months+25.54%
6 months+32.27%
Current year+32.51%
More quotes
1 week
32.85
Extreme 32.85
36.94
1 month
32.85
Extreme 32.85
39.95
Current year
23.58
Extreme 23.58
40.69
1 year
17.53
Extreme 17.53
42.63
3 years
17.53
Extreme 17.53
59.84
5 years
17.53
Extreme 17.53
70.82
10 years
4.03
Extreme 4.03
78.72
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 30/09/19
Director of Finance/CFO 39 12/07/23
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 79 14/06/15
Chairman 72 31/07/01
Director/Board Member 63 30/11/05
More insiders
Date Price Change Volume
21/06/24 36.52 +9.70% 3,750,598
20/06/24 33.29 -6.54% 2,190,299
18/06/24 35.62 +0.62% 800,126
17/06/24 35.4 -1.14% 974,799
14/06/24 35.81 -2.95% 837,667

Delayed Quote Nasdaq, June 21, 2024 at 09:00 pm

More quotes
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
36.52 USD
Average target price
38.17 USD
Spread / Average Target
+4.51%
Consensus